PRESENTATION

Q4 2021 — Presentation

Q4 2021PDF · 34 pages823 KB
DANAHER CORPORATION
Fourth Quarter 2021 Earnings Release
January 27, 2022

-- 1 of 34 --

2
Forward Looking Statements
Statements in this presentation that are not strictly historical, including any statements regarding Danaher’s anticipated future financial performance and any other statements regarding events or
developments that we anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause
actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-
looking statements. These factors include, among other things, the highly uncertain and unpredictable severity, magnitude and duration of the COVID-19 pandemic (and the related governmental, business
and community responses thereto) on our business, results of operations and financial condition, the impact of our debt obligations (including the debt incurred to finance the acquisitions of Cytiva and
Aldevron) on our operations and liquidity, deterioration of or instability in the economy, the markets we serve and the financial markets (including as a result of the COVID-19 pandemic), uncertainties relating
to U.S. laws or policies, including potential changes in U.S. trade policies and tariffs and the reaction of other countries thereto, contractions or growth rates and cyclicality of markets we serve, competition,
our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our
compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials
and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and
strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions (including
with respect to the acquisition of Aldevron), our ability to realize anticipated growth, synergies and other benefits of the Aldevron acquisition, Aldevron's performance and maintenance of important business
relationships, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future
IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow,
risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to
multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government to use, disclose and
license certain intellectual property we license if we fail to commercialize it, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, our
relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, commodity costs and surcharges, our ability to adjust purchases and
manufacturing capacity to reflect market conditions, reliance on sole sources of supply, the impact of deregulation on demand for our products and services, labor matters, international economic, political,
legal, compliance, social and business factors (including the impact of the United Kingdom's separation from the European Union), disruptions relating to man-made and natural disasters (including
pandemics such as COVID-19) and pension plan costs. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our
SEC filings, including our 2020 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2021. These forward-looking statements speak only as of the date of this presentation
and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and
developments or otherwise.
With respect to the non-GAAP financial measures referenced in the following presentation, definitions and the accompanying information required by SEC Regulation G can be found in this presentation or in
the “Investors” section of Danaher’s web site, www.danaher.com, under the heading “Financial Reports” and subheading “Quarterly Earnings.” In addition, in addressing various financial metrics the
presentation describes certain of the more significant factors that impacted year-over-year performance. For additional factors that impacted year-over-year performance, please refer to our earnings release
and the other related presentation materials supplementing today’s call, all of which are available in the “Investors” section of Danaher’s web site under the heading “Financial Reports” and subheading
“Quarterly Earnings,” as well as our Annual Report on Form 10-K for the year ended December 31, 2021 when it becomes available. All references in this presentation (1) to financial metrics relate only to the
continuing operations of Danaher’s business, unless otherwise noted; and (2) to “growth” or other period-to-period changes refer to year-over-year comparisons unless otherwise indicated. We may also
describe certain products and devices which have applications submitted and pending for certain regulatory approvals.

-- 2 of 34 --

2021 Performance Summary: Revenue
$22,284
$29,453
FY 2020 	FY 2021
$6,760
$8,148
Q4 2020 	Q4 2021
+32.0%
Core including Cytiva +25.0%
FX +1.5%
Throughout this presentation, with respect to revenue performance, for the definitions of “Acquisitions,” “Core,” "Core including Cytiva," and “FX,” please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "Investors"
section of Danaher's website.
($ millions)
Q4 REVENUE FY REVENUE
+20.5%
Core +19.5%
Acquisitions +2.0%
FX -1.0%
($ millions)

-- 3 of 34 --

2021 Performance Summary: Operating Profit Margin
23.7% 26.4%
Q4 2020 	Q4 2021
+270 BPS
Core +240 bps
Acquisitions -25 bps
Other +55 bps
Throughout this presentation when referred to in connection with operating profit margins, “Acquisitions” refers to the impact of businesses owned for less than one year or disposed of during such period and not treated as discontinued operations, "Other" refers to the impact of certain 2020 and 2021
acquisition-related fair value adjustments and transaction costs deemed significant associated with the acquisitions of Cytiva and Aldevron, impairment charges incurred in 2021 net of impairment charges incurred in 2020 and a modification and partial termination of a prior commercial arrangement and
the resolution of the associated litigation, and “Core” refers to all other year-over-year operating profit margin changes; for further description of these items, please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" section of
Danaher's website.
19.0%
25.3%
FY 2020 	FY 2021
+630 BPS
Q4 OPERATING PROFIT MARGIN FY OPERATING PROFIT MARGIN
Core +560 bps
Acquisitions +60 bps
Other +10 bps

-- 4 of 34 --

2021 Performance Summary: Adjusted Diluted Net EPS
$6.31
$10.05
FY 2020 	FY 2021
$2.08
$2.69
Q4 2020 	Q4 2021
+29.0% +59.0%
For the definition of Adjusted Diluted Net EPS, please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" section of Danaher's website.
Q4 ADJUSTED DILUTED NET
EARNINGS PER COMMON SHARE
FY ADJUSTED DILUTED NET
EARNINGS PER COMMON SHARE

-- 5 of 34 --

2021 Performance Summary: Free Cash Flow
For the definition of Free Cash Flow, please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" section of Danaher's website.
$5,426
$7,077
FY 2020 	FY 2021
+30.5%
FY FREE CASH FLOW
($ millions)

-- 6 of 34 --

Fourth Quarter 2021: Life Sciences
24.1%
27.1%
Q4 2020 	Q4 2021
$3,361
$4,046
Q4 2020 	Q4 2021
7
+20.5%
Core +17.0%
Acquisitions +4.5%
FX -1.0%
Core +290 bps
Acquisitions -105 bps
Other +115 bps
+300 BPS
($ millions)
OPERATING PROFIT MARGIN	REVENUE

-- 7 of 34 --

Fourth Quarter 2021: Diagnostics
26.3%
31.0%
Q4 2020 	Q4 2021
$2,227
$2,881
Q4 2020 	Q4 2021
8
+29.5%
Core +29.0%
Acquisitions +1.0%
FX -0.5%
Core +415 bps
Acquisitions +55 bps
+470 BPS
($ millions)
OPERATING PROFIT MARGIN	REVENUE

-- 8 of 34 --

Fourth Quarter 2021: Environmental &
Applied Solutions
23.2%
19.1%
Q4 2020 	Q4 2021
$1,172 	$1,221
Q4 2020 	Q4 2021
9
+4.0%
Core +7.5%
Acquisitions -3.0%
FX -0.5%
Core -410 bps
-410 bps
($ millions)
OPERATING PROFIT MARGIN	REVENUE

-- 9 of 34 --

10
GUIDANCE

-- 10 of 34 --

Q & A
11

-- 11 of 34 --



-- 12 of 34 --

DANAHER CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
THREE-MONTH PERIODS AND YEARS ENDED DECEMBER 31, 2021 AND DECEMBER 31, 2020

-- 13 of 34 --

TABLE OF CONTENTS
Page
1 Core Sales Growth by Segment, Core Sales Growth Including Cytiva by Segment and Base Business Core Sales Growth
2 Forecasted Core Sales Growth and Base Business Core Sales Growth
3 Segment Sales, Operating Profit and Adjusted Operating Profit
4 Adjusted EBITDA and Adjusted EBITDA Margin
8 Other Non-GAAP Adjusted P&L Measures
14 Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
15 Year-Over-Year Core Operating Margin Changes from Continuing Operations
17 Free Cash Flow from Continuing Operations and Free Cash Flow from Continuing Operations to Net Earnings from Continuing Operations
Conversion Ratio
18 Statement Regarding Non-GAAP Measures
FORWARD-LOOKING STATEMENTS DISCLOSURE
Statements in this document that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements
within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated
by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the highly uncertain and unpredictable severity,
magnitude and duration of the COVID-19 pandemic (and the related governmental, business and community responses thereto) on our business, results of operations and financial condition, the impact of our debt
obligations (including the debt incurred to finance the acquisitions of Cytiva and Aldevron) on our operations and liquidity, deterioration of or instability in the economy, the markets we serve and the financial
markets (including as a result of the COVID-19 pandemic), uncertainties relating to U.S. laws or policies, including potential changes in U.S. trade policies and tariffs and the reaction of other countries thereto,
contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper
conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the
health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and
consummate appropriate acquisitions and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated benefits of
such acquisitions (including with respect to the acquisition of Aldevron), our ability to realize anticipated growth, synergies and other benefits of the Aldevron acquisition, Aldevron's performance and maintenance
of important business relationships, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to
past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability
to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to
multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government to use, disclose and license
certain intellectual property we license if we fail to commercialize it, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, our relationships with
and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to
reflect market conditions, reliance on sole sources of supply, the impact of deregulation on demand for our products and services, labor matters, international economic, political, legal, compliance, social and
business factors (including the impact of the United Kingdom's separation from the European Union), disruptions relating to man-made and natural disasters (including pandemics such as COVID-19) and pension
plan costs. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2020 Annual Report
on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2021. These forward-looking statements speak only as of the date of this document and except to the extent required by applicable law,
the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

-- 14 of 34 --

% Change Three-Month Period Ended December 31, 2021 vs. Comparable
2020 Period
Segments
Total Company Life Sciences Diagnostics Environmental &
Applied Solutions
Total sales growth (GAAP) 20.5 % 20.5 % 29.5 % 4.0 %
Impact of:
Acquisitions/divestitures (2.0) (4.5) (1.0) 3.0
Currency exchange rates 1.0 1.0 0.5 0.5
Core sales growth (non-GAAP) 19.5 % 17.0 % 29.0 % 7.5 %
Impact of COVID-related tailwinds (9.5)
Base business core sales growth (non-GAAP) 10.0 %
% Change Year Ended December 31, 2021 vs. Comparable 2020 Period
Segments
Total Company Life Sciences Diagnostics Environmental &
Applied Solutions
Total sales growth (GAAP) 32.0 % 41.5 % 33.0 % 8.0 %
Impact of:
Acquisitions/divestitures (7.5) (16.5) (0.5) 1.5
Currency exchange rates (1.5) (2.0) (1.5) (1.5)
Core sales growth (non-GAAP) 23.0 % 23.0 % 31.0 % 8.0 %
Impact of Cytiva sales growth (net of divested product lines) 2.0 4.5
Core sales growth including Cytiva (non-GAAP) 25.0 % 27.5 %
Impact of COVID-related tailwinds (13.5)
Base business core sales growth (non-GAAP) 11.5 %
Note: Danaher calculates period-to-period core sales growth including Cytiva by adding Cytiva sales to core sales for both the baseline and current periods. Beginning in the second quarter
of 2021, Cytiva sales are included in core sales, and therefore the measure “core sales growth including Cytiva” is no longer provided for quarterly periods beginning with the second quarter
of 2021. Therefore, the impact of Cytiva sales growth represents only the impact of Cytiva sales in the first quarter of 2021, prior to the inclusion of Cytiva sales in core sales. Impact of
COVID-related tailwinds includes revenue from COVID-19 related testing and revenues related to products that support the pursuit and production of COVID-19 related treatments and
vaccines.
DANAHER CORPORATION
Core Sales Growth by Segment, Core Sales Growth Including Cytiva by Segment and Base Business Core Sales Growth
1

-- 15 of 34 --

% Change Three-Month
Period Ending April 1,
2022 vs. Comparable
2021 Period
% Change Year Ending
December 31, 2022 vs.
Comparable 2021
Period
Core sales growth (non-GAAP) ~10% +Mid-single digit
Impact of COVID-19 related testing (Low-single digit) +Low-single digit
Base business core sales growth (non-GAAP) +High-single digit +High-single digit
1 We do not reconcile these measures to the comparable GAAP measure because of the inherent difficulty in predicting and estimating the future impact and timing of currency
translation, acquisitions and divested product lines, which would be reflected in any forecasted GAAP revenue.
Note: While we expect overall demand for the Company’s COVID-19 related products to moderate as and to the extent the pandemic subsides, as the pandemic evolves toward endemic
status we believe a level of demand for the Company’s products that support COVID-19 related vaccines and therapeutics (including initiatives that seek to prevent or mitigate similar, future
pandemics) and COVID-19 testing will continue. However, on a relative basis, we expect the level of ongoing demand for products supporting COVID-19 testing will be subject to more
fluctuations in demand than the level of demand for products supporting COVID-19 related vaccines and therapeutics. Therefore, beginning with the first quarter of 2022, in addition to
disclosing core revenue growth (as defined below), we will also disclose “base business core revenue growth” on a basis that excludes revenues related to COVID-19 testing and includes
revenues from products that support COVID-19 related vaccines and therapeutics. We believe this additional measure will provide useful information to investors by facilitating period-to-
period comparisons of our financial performance and identifying underlying growth trends in the Company’s business that otherwise may be obscured by fluctuations in demand for
COVID-19 testing as a result of the pandemic.
DANAHER CORPORATION
Forecasted Core Sales Growth and Base Business Core Sales Growth 1
2

-- 16 of 34 --

Sales (GAAP)
Life Sciences $ 4,046 $ 3,361 $ 14,958 $ 10,576
Diagnostics 2,881 2,227 9,844 7,403
Environmental & Applied Solutions 1,221 1,172 4,651 4,305
Total Company $ 8,148 $ 6,760 $ 29,453 $ 22,284
Operating Profit (GAAP)
Life Sciences $ 1,097 $ 811 $ 4,367 $ 2,054
Diagnostics 893 586 2,313 1,538
Environmental & Applied Solutions 233 272 1,054 979
Other (69) (68) (269) (340)
Total Company $ 2,154 $ 1,601 $ 7,465 $ 4,231
Amortization of Intangible Assets (GAAP)
Life Sciences $ 328 $ 269 $ 1,183 $ 870
Diagnostics 51 51 205 205
Environmental & Applied Solutions 15 16 62 63
Total Company $ 394 $ 336 $ 1,450 $ 1,138
Other Operating Profit Adjustments 2
Life Sciences $ 13 $ 49 $ 104 $ 509
Diagnostics — — 557 5
Environmental & Applied Solutions — — — 17
Other — — — 59
Total Company $ 13 $ 49 $ 661 $ 590
Adjusted Operating Profit (non-GAAP) 3
Life Sciences $ 1,438 $ 1,129 $ 5,654 $ 3,433
Diagnostics 944 637 3,075 1,748
Environmental & Applied Solutions 248 288 1,116 1,059
Other (69) (68) (269) (281)
Total Company $ 2,561 $ 1,986 $ 9,576 $ 5,959
Three-Month Period Ended Year Ended
December 31, 2021 December 31, 2020 December 31, 2021 December 31, 2020
2 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted Operating Profit (non-GAAP) is defined as operating profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as
defined).
DANAHER CORPORATION
Segment Sales, Operating Profit and Adjusted Operating Profit
($ in millions)
3

-- 17 of 34 --

Three-Month Period Ended December 31, 2021
Life Sciences Diagnostics
Environmental
& Applied
Solutions Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 1,788
Interest, Net 55
Other Nonoperating (Income) Expense 4 14
Income Taxes 297
Operating Profit (GAAP) $ 1,097 $ 893 $ 233 $ (69) $ 2,154
Other Operating Profit Adjustments 2 13 — — — 13
Depreciation 71 109 11 2 193
Amortization of Intangible Assets 328 51 15 — 394
Adjusted EBITDA (Non-GAAP) $ 1,509 $ 1,053 $ 259 $ (67) $ 2,754
Interest, Net (55)
Other Nonoperating Income (Expense) 4 (14)
Income Taxes (297)
Other Operating Profit Adjustments 2 (13)
Depreciation (193)
Amortization of Intangible Assets (394)
Net Earnings from Continuing Operations (GAAP) $ 1,788
Sales (GAAP) $ 4,046 $ 2,881 $ 1,221 $ 8,148
Net Earnings from Continuing Operations Margin (GAAP) 21.9 %
Adjusted EBITDA Margin (Non-GAAP) 5 37.3 % 36.5 % 21.2 % 33.8 %
2 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
4 Other Nonoperating (Income) Expense includes loss on early extinguishment of borrowings.
5 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Adjusted EBITDA and Adjusted EBITDA Margin
($ in millions)
4

-- 18 of 34 --

Three-Month Period Ended December 31, 2020
Life Sciences Diagnostics
Environmental
& Applied
Solutions Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 1,241
Interest, Net 68
Other Nonoperating (Income) Expense 4 (9)
Income Taxes 301
Operating Profit (GAAP) $ 811 $ 586 $ 272 $ (68) $ 1,601
Other Operating Profit Adjustments 2 49 — — — 49
Depreciation 51 106 12 3 172
Amortization of Intangible Assets 269 51 16 — 336
Adjusted EBITDA (Non-GAAP) $ 1,180 $ 743 $ 300 $ (65) $ 2,158
Interest, Net (68)
Other Nonoperating Income (Expense) 4 9
Income Taxes (301)
Other Operating Profit Adjustments 2 (49)
Depreciation (172)
Amortization of Intangible Assets (336)
Net Earnings from Continuing Operations (GAAP) $ 1,241
Sales (GAAP) $ 3,361 $ 2,227 $ 1,172 $ 6,760
Net Earnings from Continuing Operations Margin (GAAP) 18.4 %
Adjusted EBITDA Margin (Non-GAAP) 5 35.1 % 33.4 % 25.6 % 31.9 %
2 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
4 Other Nonoperating (Income) Expense includes loss on early extinguishment of borrowings.
5 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Adjusted EBITDA and Adjusted EBITDA Margin
($ in millions)
5

-- 19 of 34 --

Year Ended December 31, 2021
Life Sciences Diagnostics
Environmental
& Applied
Solutions Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 6,347
Interest, Net 227
Other Nonoperating (Income) Expense 4 (360)
Income Taxes 1,251
Operating Profit (GAAP) $ 4,367 $ 2,313 $ 1,054 $ (269) $ 7,465
Other Operating Profit Adjustments 2 104 557 — — 661
Depreciation 258 409 44 7 718
Amortization of Intangible Assets 1,183 205 62 — 1,450
Adjusted EBITDA (Non-GAAP) $ 5,912 $ 3,484 $ 1,160 $ (262) $ 10,294
Interest, Net (227)
Other Nonoperating Income (Expense) 4 360
Income Taxes (1,251)
Other Operating Profit Adjustments 2 (661)
Depreciation (718)
Amortization of Intangible Assets (1,450)
Net Earnings from Continuing Operations (GAAP) $ 6,347
Sales (GAAP) $ 14,958 $ 9,844 $ 4,651 $ 29,453
Net Earnings from Continuing Operations Margin (GAAP) 21.5 %
Adjusted EBITDA Margin (Non-GAAP) 5 39.5 % 35.4 % 24.9 % 35.0 %
2 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
4 Other Nonoperating (Income) Expense includes loss on early extinguishment of borrowings.
5 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Adjusted EBITDA and Adjusted EBITDA Margin
($ in millions)
6

-- 20 of 34 --

Year Ended December 31, 2020
Life Sciences Diagnostics
Environmental
& Applied
Solutions Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 3,646
Interest, Net 204
Other Nonoperating (Income) Expense 4 (468)
Income Taxes 849
Operating Profit (GAAP) $ 2,054 $ 1,538 $ 979 $ (340) $ 4,231
Other Operating Profit Adjustments 2 509 5 17 59 590
Depreciation 183 397 47 10 637
Amortization of Intangible Assets 870 205 63 — 1,138
Adjusted EBITDA (Non-GAAP) $ 3,616 $ 2,145 $ 1,106 $ (271) $ 6,596
Interest, Net (204)
Other Nonoperating Income (Expense) 4 468
Income Taxes (849)
Other Operating Profit Adjustments 2 (590)
Depreciation (637)
Amortization of Intangible Assets (1,138)
Net Earnings from Continuing Operations (GAAP) $ 3,646
Sales (GAAP) $ 10,576 $ 7,403 $ 4,305 $ 22,284
Net Earnings from Continuing Operations Margin (GAAP) 16.4 %
Adjusted EBITDA Margin (Non-GAAP) 5 34.2 % 29.0 % 25.7 % 29.6 %
2 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
4 Other Nonoperating (Income) Expense includes loss on early extinguishment of borrowings.
5 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Adjusted EBITDA and Adjusted EBITDA Margin
($ in millions)
7

-- 21 of 34 --

Three-Month Period Ended December 31, 2021
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
from
continuing
operations
before
income taxes Income taxes
Net earnings from
continuing
operations for
calculation of
diluted earnings
per common share
Diluted net
earnings per
common
share from
continuing
operations 6
Reported (GAAP) $ 8,148 $ (3,205) 60.7 % $ 2,154 26.4 % $ 2,085 $ (297) $ 1,767 K $ 2.39
Amortization of acquisition-related
intangible assets A — — — 394 4.8 394 394 0.53
Acquisition-related items B — 13 0.2 13 0.2 13 13 0.02
Fair value net (gains) losses on
investments D — — — — — (71) (71) (0.10)
Loss on early extinguishment of debt G — — — — — 96 96 0.13
Tax effect of the above adjustments H (91) (91) (0.12)
Discrete tax adjustments I (120) (120) (0.16)
MCPS "as if converted" J — — — — — — — 21 —
Rounding — — (0.1) — — — — — —
Adjusted (Non-GAAP) $ 8,148 $ (3,192) 60.8 % $ 2,561 31.4 % $ 2,517 $ (508) $ 2,009 $ 2.69
Three-Month Period Ended December 31, 2021
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Nonoperating
income
(expense) 4,
net (excluding
interest)
Interest
income
(expense), net
Reported (GAAP) $ 8,148 $ (2,294) (28.2) % $ (495) (6.1) % $ (14) $ (55)
Amortization of acquisition-related
intangible assets A — 394 4.8 — — — —
Fair value net (gains) losses on
investments D — — — — — (71) —
Loss on early extinguishment of debt G — — — — — 96 —
Rounding — — 0.1 — — — —
Adjusted (Non-GAAP) $ 8,148 $ (1,900) (23.3) % $ (495) (6.1) % $ 11 $ (55)
4 Other Nonoperating (Income) Expense includes loss on early extinguishment of borrowings.
6 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock. Net earnings per
diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
8

-- 22 of 34 --

Three-Month Period Ended December 31, 2020
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
from
continuing
operations
before income
taxes Income taxes
Net earnings from
continuing
operations for
calculation of
diluted earnings
per common share
Diluted net
earnings per
common
share from
continuing
operations 6
Reported (GAAP) $ 6,760 $ (2,806) 58.5 % $ 1,601 23.7 % $ 1,542 $ (301) $ 1,200 K $ 1.66
Amortization of acquisition-related
intangible assets A — — — 336 5.0 336 336 0.45
Acquisition-related items B 9 40 0.6 49 0.7 49 49 0.06
Fair value net (gains) losses on
investments D — — — — — (31) (31) (0.04)
Loss on early extinguishment of debt G — — — — — 26 26 0.04
Tax effect of the above adjustments H (75) (75) (0.10)
MCPS "as if converted" J — — — — — — — 41 0.01
Rounding — — — (0.1) — — — —
Adjusted (Non-GAAP) $ 6,769 $ (2,766) 59.1 % $ 1,986 29.3 % $ 1,922 $ (376) $ 1,546 $ 2.08
Three-Month Period Ended December 31, 2020
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Nonoperating
income
(expense) 4,
net (excluding
interest)
Interest
income
(expense), net
Reported (GAAP) $ 6,760 $ (1,957) (28.9) % $ (396) (5.9) % $ 9 $ (68)
Amortization of acquisition-related
intangible assets A — 336 5.0 — — — —
Acquisition-related items B 9 — — — — — —
Fair value (gains) losses on investments D — — — — — (31) —
Loss on early extinguishment of debt G — — — — — 26 —
Adjusted (Non-GAAP) $ 6,769 $ (1,621) (23.9) % $ (396) (5.9) % $ 4 $ (68)
4 Other Nonoperating (Income) Expense includes loss on early extinguishment of borrowings.
6 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock. Net earnings per
diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
9

-- 23 of 34 --

Year Ended December 31, 2021
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings from
continuing
operations
before
income taxes Income taxes
Net earnings from
continuing
operations for
calculation of
diluted earnings
per common share
Diluted net
earnings per
common
share from
continuing
operations 6
Reported (GAAP) $ 29,453 $ (11,501) 61.0 % $ 7,465 25.3 % $ 7,598 $ (1,251) $ 6,261 K $ 8.50
Amortization of acquisition-related
intangible assets A — — — 1,450 4.9 1,450 1,450 1.95
Acquisition-related items B 17 59 0.3 104 0.4 104 104 0.14
Impairments C — — — 10 — 10 10 0.01
Fair value net (gains) losses on investments D — — — — — (401) (401) (0.54)
Gain on disposition of certain product lines E — — — — — (13) (13) (0.02)
Contract settlement expense F — — — 547 1.9 547 547 0.73
Loss on early extinguishment of debt G — — — — — 96 96 0.13
Tax effect of the above adjustments H (383) (383) (0.51)
Discrete tax adjustments I (263) (263) (0.35)
MCPS "as if converted" J — — — — — — — 86 0.01
Rounding — — (0.1) — — — — — —
Adjusted (Non-GAAP) $ 29,470 $ (11,442) 61.2 % $ 9,576 32.5 % $ 9,391 $ (1,897) $ 7,494 $ 10.05
Year Ended December 31, 2021
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Other
operating
expenses
Other
operating
expenses as a
% of sales
Nonoperating
income (expense)4,
net (excluding
interest)
Interest
income
(expense), net
Reported (GAAP) $ 29,453 $ (8,198) (27.8) % $ (1,742) (5.9) % $ (547) (1.9) % $ 360 $ (227)
Amortization of acquisition-related
intangible assets A — 1,450 4.9 — — — — — —
Acquisition-related items B 17 28 0.1 — — — — — —
Impairments C — 10 — — — — — — —
Fair value net (gains) losses on investments D — — — — — — — (401) —
Gain on disposition of certain product lines E — — — — — — — (13) —
Contract settlement expense F — — — — — 547 1.9 — —
Loss on early extinguishment of debt G — — — — — — — 96 —
Adjusted (Non-GAAP) $ 29,470 $ (6,710) (22.8) % $ (1,742) (5.9) % $ — — % $ 42 $ (227)
4 Other Nonoperating (Income) Expense includes loss on early extinguishment of borrowings.
6 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock. Net earnings per
diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
10

-- 24 of 34 --

Year Ended December 31, 2020
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings from
continuing
operations
before
income taxes Income taxes
Net earnings from
continuing
operations for
calculation of
diluted earnings
per common share
Diluted net
earnings per
common
share from
continuing
operations 6
Reported (GAAP) $ 22,284 $ (9,809) 56.0 % $ 4,231 19.0 % $ 4,495 $ (849) $ 3,511 K $ 4.89
Amortization of acquisition-related
intangible assets A — — — 1,138 5.1 1,138 1,138 1.55
Acquisition-related items B 52 457 2.1 568 2.5 568 568 0.77
Impairments C — — — 22 0.1 22 22 0.03
Fair value net (gains) losses on
investments D — — — — — (18) (18) (0.02)
Gain on disposition of certain product
lines E — — — — — (455) (455) (0.62)
Loss on early extinguishment of debt G — — — — — 26 26 0.04
Tax effect of the above adjustments H (198) (198) (0.27)
Discrete tax adjustments I (85) (85) (0.12)
MCPS "as if converted" J — — — — — — — 136 0.06
Adjusted (Non-GAAP) $ 22,336 $ (9,352) 58.1 % $ 5,959 26.7 % $ 5,776 $ (1,132) $ 4,645 $ 6.31
Year Ended December 31, 2020
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Nonoperating
income
(expense) 4,
net (excluding
interest)
Interest
income
(expense), net
Reported (GAAP) $ 22,284 $ (6,896) (30.9) % $ (1,348) (6.0) % $ 468 $ (204)
Amortization of acquisition-related
intangible assets A — 1,138 5.1 — — — —
Acquisition-related items B 52 59 0.3 — — — —
Impairments C — 22 0.1 — — — —
Fair value net (gains) losses on
investments D — — — — — (18) —
Gain on disposition of certain product
lines E — — — — — (455) —
Loss on early extinguishment of debt G — — — — — 26 —
Adjusted (Non-GAAP) $ 22,336 $ (5,677) (25.4) % $ (1,348) (6.0) % $ 21 $ (204)
4 Other Nonoperating (Income) Expense includes loss on early extinguishment of borrowings.
6 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock. Net earnings per
diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
11

-- 25 of 34 --

A Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in
the amortization line item above):
Three-Month Period Ended Year Ended
December 31, 2021 December 31, 2020 December 31, 2021 December 31, 2020
Pretax $ 394 $ 336 $ 1,450 $ 1,138
After-tax 315 270 1,157 915
B Costs incurred for fair value adjustments to inventory related to the acquisition of Aldevron in the three-month period ended December 31, 2021, ($13 million
pretax as reported in this line item, $10 million after-tax). Costs incurred for fair value adjustments to inventory and deferred revenue and transaction costs
deemed significant related to the acquisitions of Cytiva and Aldevron in the year ended December 31, 2021, ($104 million pretax as reported in this line item,
$82 million after-tax). Costs incurred for fair value adjustments to inventory and deferred revenue related to the acquisition of Cytiva in the three-month period
ended December 31, 2020, ($49 million pretax as reported in this line item, $39 million after-tax) and fair value adjustments to inventory and deferred revenue,
transaction costs deemed significant and integration preparation costs related to the acquisition of Cytiva for the year ended December 31, 2020, ($568 million
pretax as reported in this line item, $450 million after-tax). The Company deems acquisition-related transaction costs incurred in a given period to be significant
(generally relating to the Company’s larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for
Danaher in a given period.
C Impairment charges related to a trade name in the Diagnostics segment recorded in the year ended December 31, 2021, ($10 million pretax as reported in this line
item, $8 million after-tax). Impairment charges related to a facility in the Diagnostics segment and trade names and other intangibles assets in the Environmental
& Applied Solutions segment recorded in the year ended December 31, 2020, ($22 million pretax as reported in this line item, $17 million after-tax).
D Net gains/losses on the Company's equity and limited partnership investments in the following historical periods (in $ millions) (only the pretax amounts set forth
below are reflected in the fair value net gains/losses on investments line above):
Three-Month Period Ended Year Ended
December 31, 2021 December 31, 2020 December 31, 2021 December 31, 2020
Pretax (gain)/loss $ (71) $ (31) $ (401) $ (18)
After-tax (gain)/loss (57) (24) (315) (14)
E Gain on disposition of certain product lines in the year ended December 31, 2021, ($13 million pretax as reported in this line item, $10 million after-tax). Gain
on disposition of certain product lines in the year ended December 31, 2020, ($455 million pretax as reported in this line item, $305 million after-tax).
F Expense related to the modification and partial termination of prior commercial arrangements and resolution of an associated litigation in the year ended
December 31, 2021, ($547 million pretax as reported in this line item, $415 million after-tax).
G Loss on early extinguishment of debt resulting from “make-whole” payments and deferred costs associated with the retirement of the 2025 Euronotes in both the
three-month period and the year ended December 31, 2021, ($96 million pretax as reported in this line item, $73 million after-tax). Loss on early extinguishment
of debt resulting from “make-whole” payments and deferred costs associated with the retirement of the 2022 Euronotes in both the three-month period and the
year ended December 31, 2020, ($26 million pretax as reported in this line item, $20 million after-tax).
H This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnotes above
indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher’s overall
estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application
of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment. The MCPS
dividends are not tax deductible and therefore the tax effect of the adjustments does not include any tax impact of the MCPS dividends.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
12

-- 26 of 34 --

I Discrete tax adjustments and other tax-related adjustments for both the three-month period and year ended December 31, 2021, include the impact of net discrete
tax benefits of $120 million (or $0.16 per diluted common share), and $263 million (or $0.35 per diluted common share), respectively, related primarily to release
of reserves for uncertain tax positions due to the expiration of statutes of limitation and audit settlements, excess tax benefits from stock-based compensation and
the mix of earnings between the U.S. and certain jurisdictions with lower overall tax rates, net of changes in estimates associated with prior period uncertain tax
positions. Discrete tax adjustments and other tax-related adjustments for the year ended December 31, 2020, include the impact of net discrete tax benefits of
$85 million (or $0.12 per diluted common share) related primarily related to the release of reserves for uncertain tax positions from audit settlements and
expiration of statutes of limitation and excess tax benefits from stock-based compensation, partially offset by a higher tax rate associated with the gain on the
divestiture of certain product lines in the Life Sciences segment and changes in estimates associated with prior period uncertain tax positions. The Company
anticipates excess tax benefits from stock compensation of approximately $7 million per quarter and therefore excludes benefits in excess of this amount in the
calculation of adjusted diluted net earnings from continuing operations per common share.
J In March 2019, the Company issued $1.65 billion in aggregate liquidation preference of 4.75% MCPS Series A. In May 2020, the Company issued $1.72 billion
in aggregate liquidation preference of 5.0% MCPS Series B. Dividends on the MCPS Series A and Series B are payable on a cumulative basis at an annual rate
of 4.75% and 5.0%, respectively, on the liquidation preference of $1,000 per share. Unless earlier converted, each share of MCPS Series A will automatically
convert on April 15, 2022 into between 6.6611 and 8.1598 shares of Danaher’s common stock, subject to further anti-dilution adjustments. Unless earlier
converted, each share of MCPS Series B will automatically convert on April 15, 2023 into between 5.0103 and 6.1376 shares of Danaher’s common stock,
subject to further anti-dilution adjustments. The number of shares of Danaher’s common stock issuable on conversion of the MCPS will be determined based on
the volume weighted average price (“VWAP”) per share of the Company's common stock over the 20 consecutive trading day period beginning on, and
including, the 21st scheduled trading day immediately before April 15, 2022 and April 15, 2023 for the MCPS Series A and Series B, respectively. For the
calculation of net earnings per common share from continuing operations, the impact of the dilutive MCPS is calculated under the if-converted method and the
related MCPS dividends are excluded. For the purposes of calculating adjusted earnings per common share from continuing operations, the Company has
excluded the paid and anticipated MCPS cash dividends and assumed the “if-converted” method of share dilution (the incremental shares of common stock
deemed outstanding applying the “if-converted” method of calculating share dilution only with respect to any MCPS the conversion of which would be dilutive
in the particular period are referred to as the “Converted Shares”) for any MCPS that were anti-dilutive for the given period. For additional information about the
impact of the MCPS on the calculation of diluted EPS, see note 7 in the Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
table below.
K Net earnings from continuing operations for calculation of diluted earnings per common share is summarized as follows ($ in millions):
Three-Month Period Ended Year Ended
December 31, 2021 December 31, 2020 December 31, 2021 December 31, 2020
Net earnings from continuing operations $ 1,788 $ 1,241 $ 6,347 $ 3,646
MCPS dividends (41) (41) (164) (136)
Net earnings from continuing operations attributable to common stockholders for
Basic EPS 1,747 1,200 6,183 3,510
Adjustment for interest on convertible debentures — — — 1
Adjustment for MCPS dividends for dilutive MCPS 20 — 78 —
Net earnings from continuing operations attributable to common stockholders after
assumed conversions for Diluted EPS $ 1,767 $ 1,200 $ 6,261 $ 3,511
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
13

-- 27 of 34 --

Three-Month Period Ended Year Ended
December 31, 2021 December 31, 2020 December 31, 2021 December 31, 2020
Average common stock and common equivalent shares outstanding - diluted (GAAP) 7 738.4 724.5 736.8 718.7
Converted shares 8 8.6 19.6 8.6 17.1
Adjusted average common stock and common equivalent shares outstanding - diluted (non-
GAAP) 747.0 744.1 745.4 735.8
7 The impact of the MCPS Series A calculated under the if-converted method was dilutive for the three-month period and year ended December 31, 2021, and as such 11.0 million shares
underlying the MCPS Series A were included in the calculation of diluted EPS in both periods and the related MCPS Series A dividends of $20 million and $78 million were excluded
from the calculation of net earnings for diluted EPS for the respective periods.
The impact of the MCPS Series B calculated under the if-converted method was anti-dilutive for the three-month period and year ended December 31, 2021, and as such 8.6 million
shares underlying the MCPS Series B were excluded from the diluted EPS calculation in both periods and the related MCPS Series B dividends of $21 million and $86 million were
included in the calculation of net earnings for diluted EPS for the respective periods.
The impact of the MCPS Series A and MCPS Series B calculated under the if-converted method was anti-dilutive for the three-month period and year-ended December 31, 2020, and as
such, 19.6 million shares and 17.1 million shares, respectively underlying the MCPS Series A and Series B were excluded from the calculation of diluted EPS for the periods and the
related MCPS Series A and Series B dividends of $41 million and $136 million, respectively, were included in the calculation of net earnings for diluted EPS for the periods.
8 The number of converted shares assumes the conversion of all MCPS and issuance of the underlying shares applying the “if-converted” method of accounting and using an average 20
trading-day trailing VWAP of $316.06 and $223.43 as of December 31, 2021 and December 31, 2020, respectively.
DANAHER CORPORATION
Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
(shares in millions)
14

-- 28 of 34 --

Segments
Total Company Life Sciences Diagnostics
Environmental
& Applied
Solutions
Three-Month Period Ended December 31, 2020 Operating Profit Margins from Continuing
Operations (GAAP) 23.70 % 24.10 % 26.30 % 23.20 %
Fourth quarter 2021 impact from operating profit margins of businesses that have been owned for
less than one year or were disposed of during such period and did not qualify as discontinued
operations (0.25) (1.05) 0.55 —
Fourth quarter 2021 acquisition-related fair value adjustment to inventory deemed significant
related to the acquisition of Aldevron (0.15) (0.30) — —
Fourth quarter 2020 acquisition-related fair value adjustments to inventory and deferred revenue,
in each case related to the acquisition of Cytiva 0.70 1.45 — —
Year-over-year core operating profit margin changes for the fourth quarter 2021 (defined as
all year-over-year operating profit margin changes other than the changes identified in the line
items above) (non-GAAP) 2.40 2.90 4.15 (4.10)
Three-Month Period Ended December 31, 2021 Operating Profit Margins from Continuing
Operations (GAAP) 26.40 % 27.10 % 31.00 % 19.10 %
Note: The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company’s larger acquisitions) if it
determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.
DANAHER CORPORATION
Year-Over-Year Core Operating Margin Changes from Continuing Operations
15

-- 29 of 34 --

Segments
Total Company Life Sciences Diagnostics
Environmental
& Applied
Solutions
Year Ended December 31, 2020 Operating Profit Margins from Continuing Operations
(GAAP) 19.00 % 19.40 % 20.80 % 22.70 %
Full year 2021 impact from operating profit margins of businesses that have been owned for less
than one year or were disposed of during such period and did not qualify as discontinued
operations 0.60 0.80 0.20 —
Full year 2021 acquisition-related fair value adjustments to inventory and transaction costs
deemed significant, in each case related to the acquisition of Aldevron (0.20) (0.40) — —
Full year 2020 acquisition-related fair value adjustments to inventory and deferred revenue,
transaction costs deemed significant and integration preparation costs, net of full year 2021
acquisition-related fair value adjustments to inventory and deferred revenue in each case related
to the acquisition of Cytiva 2.10 4.40 — —
Third quarter 2021 impact of the modification and partial termination of a prior commercial
arrangement and resolution of the associated litigation (1.85) — (5.55) —
First quarter 2020 impairment charges related to a facility in the Diagnostics segment and a trade
name and other intangible assets in the Environmental & Applied Solutions segment and a third
quarter 2020 impairment charge related to trade names in the Environmental & Applied
Solutions segment, net of a first quarter 2021 impairment charge related to a trade name in the
Diagnostics segment. 0.05 — (0.05) 0.45
Year-over-year core operating profit margin changes for full year 2021 (defined as all year-
over-year operating profit margin changes other than the changes identified in the line items
above) (non-GAAP) 5.60 5.00 8.10 (0.45)
Year Ended December 31, 2021 Operating Profit Margins from Continuing Operations (GAAP) 25.30 % 29.20 % 23.50 % 22.70 %
Note: The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company’s larger acquisitions) if it
determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.
DANAHER CORPORATION
Year-Over-Year Core Operating Margin Changes from Continuing Operations
16

-- 30 of 34 --

Three-Month Period Ended
Year-over-Year
Change
Year Ended
Year-over-Year
Change
December 31,
2021 December 31,
2020 December 31,
2021 December 31,
2020
Total Cash Flows from Continuing Operations:
Total cash provided by operating activities from continuing
operations (GAAP) $ 2,333 $ 2,221 $ 8,358 $ 6,215
Total cash used in investing activities from continuing operations
(GAAP) $ (879) $ (581) $ (12,987) $ (21,239)
Total cash (used in) provided by financing activities from
continuing operations (GAAP) $ (1,422) $ (1,420) $ 1,295 $ 1,006
Free Cash Flow from Continuing Operations:
Total cash provided by operating activities from continuing
operations (GAAP) $ 2,333 $ 2,221 ~5.0 % $ 8,358 $ 6,215 ~34.5%
Less: payments for additions to property, plant & equipment
(capital expenditures) from continuing operations (GAAP) (420) (316) (1,294) (791)
Plus: proceeds from sales of property, plant & equipment (capital
disposals) from continuing operations (GAAP) — 1 13 2
Free cash flow from continuing operations (non-GAAP) $ 1,913 $ 1,906 ~0.5 % $ 7,077 $ 5,426 ~30.5%
Free Cash Flow from Continuing Operations to Net Earnings
from Continuing Operations Conversion Ratio:
Free cash flow from continuing operations from above (non-
GAAP) $ 1,913 $ 1,906 $ 7,077 $ 5,426
Net earnings from continuing operations (GAAP) 1,788 1,241 6,347 3,646
Free cash flow from continuing operations to net earnings from
continuing operations conversion ratio (non-GAAP) 1.07 1.54 1.12 1.49
We define free cash flow as operating cash flows from continuing operations, less payments for additions to property, plant and equipment from continuing operations (“capital
expenditures”) plus the proceeds from sales of plant, property and equipment from continuing operations (“capital disposals”). All amounts presented above reflect only continuing
operations.
DANAHER CORPORATION
Free Cash Flow from Continuing Operations and Free Cash Flow from Continuing Operations to Net Earnings from Continuing Operations Conversion Ratio
($ in millions)
17

-- 31 of 34 --

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may
not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering
additional ways of viewing Danaher Corporation’s (“Danaher” or the “Company”) results that, when reconciled to the corresponding GAAP measure, help our investors
to:
• with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to prior
and future periods and to our peers;
• with respect to core sales and related sales measures, identify underlying growth trends in our business and compare our sales performance with prior and future
periods and to our peers; and
• with respect to free cash flow from continuing operations and related cash flow measures (the “FCF Measure”), understand Danaher’s ability to generate cash
without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities
(although a limitation of free cash flow is that it does not take into account the Company’s debt service requirements and other non-discretionary expenditures,
and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures).
We also present core sales on a basis that includes sales attributable to Cytiva (formerly the Biopharma Business of General Electric Company’s (“GE”) Life Sciences
business), which Danaher acquired from GE on March 31, 2020. Historically Danaher has calculated core sales solely on a basis that excludes sales from acquired
businesses recorded prior to the first anniversary of the acquisition. However, given Cytiva’s significant size and historical core sales growth rate, in each case compared
to Danaher’s existing businesses, management believes it is appropriate to also present core sales on a basis that includes Cytiva sales. Management believes this
presentation provides useful information to investors by demonstrating beginning immediately after the acquisition Cytiva’s impact on the Company’s growth profile,
rather than waiting to demonstrate such impact 12 months after the acquisition when Cytiva would normally have been included in Danaher’s core sales calculation.
Danaher calculates period-to-period core sales growth including Cytiva by adding to the baseline period sales Cytiva’s historical sales from such period (when it was
owned by GE), net of the sales of the Company product lines divested in 2020 to obtain regulatory approval to acquire Cytiva (“Cytiva sales”) and also adding the Cytiva
sales to the current period. Beginning in the second quarter of 2021, Cytiva sales are included in core sales, and therefore we no longer provide the measure “core sales
including Cytiva” for quarterly periods beginning with the second quarter of 2021. We also present “base business” core revenue growth to demonstrate our core revenue
growth and our core revenue growth including Cytiva excluding core sales growth directly attributable to COVID-19 and its impact.
While we expect overall demand for the Company’s COVID-19 related products to moderate as and to the extent the pandemic subsides, as the pandemic evolves toward
endemic status we believe a level of demand for the Company’s products that support COVID-19 related vaccines and therapeutics (including initiatives that seek to
prevent or mitigate similar, future pandemics) and COVID-19 testing will continue. However, on a relative basis, we expect the level of ongoing demand for products
supporting COVID-19 testing will be subject to more fluctuations in demand than the level of demand for products supporting COVID-19 related vaccines and
therapeutics. Therefore, beginning with the first quarter of 2022, in addition to disclosing core revenue growth (as defined below), we will also disclose “base business
core revenue growth” on a basis that excludes revenues related to COVID-19 testing and includes revenues from products that support COVID-19 related vaccines and
therapeutics. We believe this additional measure will provide useful information to investors by facilitating period-to-period comparisons of our financial performance
and identifying underlying growth trends in the Company’s business that otherwise may be obscured by fluctuations in demand for COVID-19 testing as a result of the
pandemic.
Management uses these non-GAAP measures to measure the Company’s operating and financial performance, and uses core sales and non-GAAP measures similar to
Adjusted Diluted Net Earnings Per Common Share from Continuing Operations and the FCF Measure in the Company’s executive compensation program.
• The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:
DANAHER CORPORATION
Statement Regarding Non-GAAP Measures
18

-- 32 of 34 --

◦ Amortization of Intangible Assets. We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges
are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition
activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition’s purchase price allocated to intangible assets and related
amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense
facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive
and non-acquisitive peer companies. We believe however that it is important for investors to understand that such intangible assets contribute to sales
generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully
amortized.
◦ Restructuring Charges. We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic
nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from
application of the Danaher Business System. Because these restructuring plans are incremental to the core activities that arise in the ordinary course of
our business and we believe are not indicative of Danaher’s ongoing operating costs in a given period, we exclude these costs to facilitate a more
consistent comparison of operating results over time.
◦ Other Adjustments. With respect to the other items excluded from Adjusted Diluted Net Earnings Per Common Share from Continuing Operations, we
exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's
commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-
term performance difficult.
• With respect to adjusted average common stock and common equivalent shares outstanding, Danaher’s Mandatory Convertible Preferred Stock (“MCPS”) will
mandatorily convert into Danaher common stock on the mandatory conversion date, which is expected to be April 15, 2022 and April 15, 2023 for the Series A
and Series B MCPS, respectively, (unless converted or redeemed earlier in accordance with the terms of the applicable certificate of designations). With respect
to the calculation of Adjusted Diluted Net Earnings Per Common Share from Continuing Operations, we apply the “if converted” method of share dilution to the
MCPS Series A and B in all applicable periods irrespective of whether such preferred shares would be dilutive or anti-dilutive in the period. We believe this
presentation provides useful information to investors by helping them understand what the net impact will be on Danaher’s earnings per share-related measures
once the MCPS convert into Danaher common stock.
• With respect to core operating profit margin changes, in addition to the explanation set forth in the bullets above relating to the “other adjustments”, we exclude
the impact of businesses owned for less than one year (or disposed of during such period and not treated as discontinued operations) because the timing, size,
number and nature of such transactions can vary significantly from period to period and may obscure underlying business trends and make comparisons of long-
term performance difficult.
• We calculate adjusted EBITDA by adding to operating profit amounts equal to depreciation and amortization and making the other adjustments reflected in the
applicable tables above, which allows us to calculate and disclose such measure by segment. Given Danaher’s diversification, we believe this helps our investors
compare the profitability of our individual segments to peer companies with like business lines.
• With respect to core sales related measures, (1) we exclude the impact of currency translation because it is not under management’s control, is subject to
volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions (other than Cytiva, in the case of core sales including Cytiva
and base business core sales) and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-
period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult.
• With respect to the FCF Measure, we exclude payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate
the amount of operating cash flow for the period that remains after accounting for the Company’s capital expenditure requirements.
With respect to forecasted core sales related measures, we do not reconcile these measures to the comparable GAAP measure because of the inherent difficulty in
predicting and estimating the future impact and timing of currency translation, acquisitions and divested product lines, which would be reflected in any forecasted GAAP
revenue.
DANAHER CORPORATION
Statement Regarding Non-GAAP Measures
19

-- 33 of 34 --

20

-- 34 of 34 --